FDA hits Chinese drugmaker with warning letter over manufacturing issues

FDA hits Chinese drug manufacturer Wuxi Medical Instrument Factory with a warning letter.

The FDA served a warning letter to China’s Wuxi Medical Instrument Factory in response to an inspection that exposed four violations, including an infringement on procedures that involved company employees misrepresenting to inspectors the actual dates of the creation of some documents.

The inspection at the Wuxi City-based facility took place in early March.

During the inspection, the agency said in a letter to the company posted on its website this week, the FDA found that records covering January to March of this year were signed by two employees that stated sanitization had been completed and verified contemporaneously during those months.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“However, our investigator found that these operations were not documented at the time of their actual performance, but were instead created and completed on March 7, 2017, the second day of the inspection," the letter said.

The regulatory agency also said it found Wuxi Medical Instrument Factory was unable to provide process qualification batch records and quality control test documentation, and only gave inspectors "a protocol and a summary report with insufficient data.”

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality control systems.